Cargando…

Localized Rhabdomyolysis Associated With Testosterone Enanthate for Gender-Affirming Hormonal Therapy

BACKGROUND/OBJECTIVE: Rhabdomyolysis is a condition characterized by the destruction of skeletal muscle tissue that leads to systemic complications. We present a case of gender-affirming intramuscular (IM) testosterone therapy precipitating localized deltoid rhabdomyolysis. CASE REPORT: A 34-year-ol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reddy, Rashmi, Lizama-Hernández, Sergio, Port, Ava M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association of Clinical Endocrinology 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701813/ https://www.ncbi.nlm.nih.gov/pubmed/36447833 http://dx.doi.org/10.1016/j.aace.2022.09.005

Ejemplares similares

Physical and Psychological Effects of Gender-Affirming Hormonal Treatment Using Intramuscular Testosterone Enanthate in Japanese Transgender Men
por: Kirisawa, Takahiro, et al.
Publicado: (2021)

Metabolomics of testosterone enanthate administration during severe-energy deficit
por: Stein, Jesse A., et al.
Publicado: (2022)

SAT-037 Effect of Weight on Serum Testosterone with Subcutaneous Testosterone Enanthate in Men with Testosterone Deficiency
por: Bhattacharya, Rajib, et al.
Publicado: (2020)

Testosterone Enanthate: An In Vitro Study of the Effects Triggered in MG-63 Cells
por: Ghezzi, Benedetta, et al.
Publicado: (2022)

An Approach to Nonsuppressed Testosterone in Transgender Women Receiving Gender-Affirming Feminizing Hormonal Therapy
por: Maheshwari, Arvind, et al.
Publicado: (2021)

Allometric Scaling of Testosterone Enanthate Pharmacokinetics to Adolescent Hypogonadal Males (IM and SC Administration)
por: Vogiatzi, Maria G, et al.
Publicado: (2023)

OR31-03 Testosterone Gender-affirming Hormonal Therapy Is Associated With Decreased Cerebral Blood Flow In Transgender Teens
por: Cote, Samantha, et al.
Publicado: (2023)

Angiofibroma stimulation in a transgender person receiving gender-affirming testosterone
por: Bubley, Jeffrey A., et al.
Publicado: (2020)

Two Transgender Men Receiving Subdermal Testosterone Pellets for Gender Affirmation
por: Wolf Pulsiano, Sune L., et al.
Publicado: (2023)

Possible association of keratoconus progression with gender-affirming hormone therapy: A case report
por: Deitel, Carli M., et al.
Publicado: (2023)

Efficacy of Transdermal Dihydrotestosterone and Testosterone Enanthate for Penile Augmentation in Patients With Idiopathic Micropenis: A Comparative Randomized Study
por: Karrou, Marouan, et al.
Publicado: (2023)

Clinical pearls of gender-affirming hormone therapy in transgender patients
por: Irving, Amanda, et al.
Publicado: (2018)

Gender-affirming Hormone Therapy and Risk of Diabetes in Transgender Persons
por: Tangpricha, Vin
Publicado: (2022)

100. Patterns of Perioperative Hormone Therapy for Gender-affirming Surgery
por: Hung, Ya-Ching, et al.
Publicado: (2023)

Porphyria cutanea tarda unmasked by supratherapeutic estrogen during gender-affirming hormone therapy
por: Jackson Cullison, Stephanie R., et al.
Publicado: (2020)

Gender-affirming hormone therapy in cystic fibrosis – A case of new Pseudomonas infection
por: Shaffer, L., et al.
Publicado: (2021)

Breast cancer in a transgender woman undergoing gender-affirming exogenous hormone therapy
por: Villalba, Michael D., et al.
Publicado: (2023)

Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population
por: Aranda, Gloria, et al.
Publicado: (2021)

Pharmacological treatment for pubertal progression in boys with delayed or slow progression of puberty: A small-scale randomized study with testosterone enanthate and testosterone undecanoate treatment
por: Österbrand, Martin, et al.
Publicado: (2023)

LBODP090 The Addition Of Anastrozole To Standard Testosterone Enanthate Treatment Significantly Improves Penile Size In Adolescent Boys With Micropenis
por: Papadimitriou, Dimitrios T, et al.
Publicado: (2022)

Subcutaneous Testosterone Is Effective and Safe as Gender-Affirming Hormone Therapy in Transmasculine and Gender-Diverse Adolescents and Young Adults: A Single Center's 8-Year Experience
por: Laurenzano, Sarah E., et al.
Publicado: (2021)

The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis
por: Schutte, Moya H., et al.
Publicado: (2022)

The return of spermatogenesis in transgender women ceasing gender-affirming hormone therapy
por: Yau, Mabel, et al.
Publicado: (2023)

Gender-Affirming Hormone Therapy: Physical and Sociopsychological Effects, Impact and Satisfaction
por: Santos, Rafael B, et al.
Publicado: (2023)

D22. Effects of Exogenous Testosterone on Scarring in Gender-affirming Chest Surgery
por: Mroueh, Vanessa, et al.
Publicado: (2023)

Frequency and Characteristics of Postoperative Neuropathy in Individuals on Gender-Affirming Hormone Therapy Undergoing Gender Affirmation Surgery: A Retrospective Cohort Study
por: Togioka, Brandon M, et al.
Publicado: (2023)

Changes to hypothalamic volume and associated subunits during gender-affirming hormone therapy
por: Konadu, Melisande E., et al.
Publicado: (2023)

Longitudinal metabolic study of red blood cells from patients undergoing gender-affirming testosterone therapy
por: Roy, Micaela Kalani, et al.
Publicado: (2022)

Ovary stereological features and serum biochemical factors following induction of polycystic ovary syndrome with testosterone enanthate in mice: An experimental study
por: Kalhori, Zahra, et al.
Publicado: (2018)

A Review of Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults in South Korea
por: OH, Jeong-Won, et al.
Publicado: (2022)

Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults
por: Connelly, Paul J., et al.
Publicado: (2019)

Gender-affirming hormone therapy induces specific DNA methylation changes in blood
por: Shepherd, Rebecca, et al.
Publicado: (2022)

Prolactinoma in a Male to Female Transgender Woman on Gender Affirming Hormone Therapy
por: Harned, Leighton K, et al.
Publicado: (2021)

ODP148 GENDER AFFIRMING HORMONE THERAPY AND SPONTANEOUS CORONARY ARTERY DISSECTION
por: Yogeswaran, Vidhushei, et al.
Publicado: (2022)

Gender affirming hormone therapy dosing behaviors among transgender and nonbinary adults
por: Restar, Arjee, et al.
Publicado: (2022)

Successful restoration of spermatogenesis following gender-affirming hormone therapy in transgender women
por: de Nie, Iris, et al.
Publicado: (2023)

SAT413 Feminising Gender Affirming Hormone Therapy Prolongs QTc Interval
por: Angus, Lachlan, et al.
Publicado: (2023)

Cardiovascular Risk Factors in Transgender People after Gender-Affirming Hormone Therapy
por: Sánchez-Toscano, Esteban, et al.
Publicado: (2023)

Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single‐Use Autoinjector: A Phase II Study
por: Kaminetsky, Jed, et al.
Publicado: (2015)

Norethisterone enanthate-induced cerebral venous sinus thrombosis (CVST)
por: Bahall, Mandreker, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ljcetnipichi9t6dvplv71envh